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Cervical cancer is common cancer and ranked in fourth place in both incidence and mortality 
worldwide. It is 3rd most common female cancer in Malaysia with a lifetime risk of 1 in 116. 
Infection with high-risk oncogenic human papillomavirus (HPV) is recognized as one of the 
substantial risk factors for the development of cervical cancers. 
 
Methods  
It was a cross-sectional study conducted to determine the prevalence of HPV infection and its 
subtypes among women with various degrees of abnormal smears, who were seen in the 
colposcopy clinic of Sarawak General Hospital within six months’ period from January to June 
2018. We recruited 56 participants. There were 23 each for an atypical squamous cells of 
undetermined significance (ASC-US) and low-grade squamous intraepithelial lesion (LSIL) and 
10 high- grade squamous intraepithelial lesion (HSIL). DNA was extracted, and HPV genotypes 




The age ranged from 23 to 56 years, with a mean age of 42.96 years. HPV was detected in 20 out 
of 56 (35.7%). There were 6 high-risk oncogenic HPVs (18, 51, 52, 56, 58, 68) detected in 
participants and the most prevalent subtypes were 18, 52, and 58 (20% each). Four low-risk HPVs 
detected were 6, 53, 70, and 84. There was a significant association between the severity of cervical 
lesions and HPV positivity (P < 0.004). HSIL had the highest positive predictive value to have 
HPV infection as 70% compared to 43.4% of LSIL and 9.3% of ASC-US.  
 
Conclusion  
Distribution of HPV subtypes from women with abnormal smears from Sarawak indicated a high 
prevalence of HPV 18, 52, and 58. We also identified HPV 70, which has never been reported in 
West Malaysia. These findings could contribute valuable information for HPV vaccination 
strategies, particularly for Sarawakian women. 
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Cervical cancer is common cancer and ranked in fourth place in both incidence (6.6%) and 
mortality (7.5%) according to GLOBOSCAN estimates [1]. Almost 80% of cases occur in 
developing countries [2]. Globally it was estimated that more than 500,000 new cases with 300,000 
deaths from cervical cancer in the year 2018[1]. It is 3rd most common female cancer in Malaysia, 
and according to the National Cancer Registry of Malaysia (2016), Sarawak ranked as the highest 
age-standardized incidence rate for cervical cancer at 12.1 per 100,000 women [3].  
There are known risk factors such as early intercourse, sexual promiscuity, immunosuppression, 
sexually transmitted diseases, and smoking. However, above all, infection with human 
papillomavirus (HPV) plays the most crucial role in the development of cervical cancer.  
HPV is a small, highly conserved, non-enveloped double-stranded DNA virus that belongs to the 
Papillomaviridae family [4]. To date, more than 200 HPV subtypes have been identified [5]. It can 
be classified into mucosal or cutaneous, and the former being known as an important aetiological 
agent for the development of cervical cancers. Mucosal-infecting HPV is subdivided into high- 
and low-risk groups. There were at least 15 HPV subtypes identified as high-risk oncogenic HPVs 
which include subtypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82 [6].  
The HPV infection is asymptomatic in the majority of women, and most cases resolve within two 
years [7]. Some studies reported that infection spontaneously resolves in 50-90% of HPV-positive 
women in one year [8,9]. Nonetheless, 10-15% of all HPV-infected women may have persistent 
infection [7] and consecutively, increased risk of cancers, and other benign diseases. Among 15 
high-risk oncogenic HPVs, type 16 and 18 were most prevalent types associated with 70-80% of 
cervical and anal cancers, and 40-50% of vulvar and oropharyngeal cancers [10, 11]. It is pertinent 
to note that HPV infection can be transmitted through intimate skin to skin contact without having 
penetrative intercourse, and once infected, there is a lifetime risk of infection up to 85% [10].  
The prevalence of HPV infection and the distribution of subtypes varied in a wide range across the 
region and population [12]. In Southeast Asia, estimated HPV prevalence was reported as 14% 
[13]. The prevalence increases with increased severity of cervical lesions. A systematic review 
reported the prevalence of high-risk HPV 16 and 18 in cytology of Malaysian women with cervical 
cancer as 88.7% [4]. However, most of the data contributed were from West Malaysia, and there 
are currently no published data on the prevalence of HPV subtypes among women with abnormal 
smears in Sarawak.  
The objectives of our study were: a) to determine the proportion of HPV infection among women 
with various degrees of abnormal smears who were seen in Sarawak General Hospital; b) to 
identify the common HPV subtypes seen in abnormal cervical smears in Sarawak. The 
incorporation of HPV tests in the management supported the effectiveness of already implemented 
guidelines on abnormal smears management in a resource-limited area like Sarawak. At the same 
time, identifying the common subtype would help to introduce the respective vaccination program 







MATERIALS AND METHODS 
  
Study design  
It was a cross-sectional study involving all sexually active women with abnormal pap smears, who 
attended the colposcopy clinic of Sarawak General Hospital within six months period from 1st 
January to 31st June 2018. Pregnant women and those who have had prior HPV vaccination were 
excluded from the study. Ethical clearance was approved by the Medical Research and Ethics 
Committee (MREC), Ministry of Health, Malaysia (NMRR-17-1952-36173) as well as UNIMAS 
Medical Ethics Committee [UNIMAS/NC-21.02Jld.3(17)]. A patient information leaflet was 
provided to all participants. Informed consent was taken along with their sociodemographic data, 
medical and sexual history.  
  
Cervical samples  
All the samples were taken by convenience sampling method. Cervical liquid-based cytology was 
obtained as follows; the cervix was scraped 360 degrees (both endocervix and ectocervix) of each 
participant by a single gynecologist (MSY) using sterile Cervex-Brush (Rovers Medical Devices, 
Lekstraat, Netherlands). Then the Cervex-Brush was preserved in BD Surepath Medium in the 
collection vial and stored at 4 °C. The samples were sent in the cold chain to the Medical 
Microbiology Laboratory, Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak 
on a twice-weekly basis. 
  
Molecular detection of the HPV genome 
The cervical cells were dislodged and resuspended in the BD Surepath medium via vortexing in 3 
short bursts of 10 seconds each. Two mL of the cell suspension (10% of the total volume) was 
pelleted by centrifugation at 3000 x g for 30 mins at 4 °C. The supernatant was carefully discarded 
by aspiration, and cells resuspended in sterile phosphate-buffered saline (PBS). The viral nucleic 
acid was extracted from the cell suspension using the High Pure Viral Nucleic Acid Kit (Roche) 
according to the manufacturer’s instruction.  
In our study, we used two different pairs of oligonucleotides primers to detect HPV DNA: 
MY09/MY11, followed by GP5+/GP6+. Polymerase chain reactions (PCR) were carried out 
separately for each oligonucleotide primer as previously described by Venceslau et al [14]. Primer 
set amplifying human ß-globin gene was included as an internal control. Amplicons were resolved 
in 2 % (w/v) agarose gel prepared in TBE buffer, excised, and sequenced using the BigDyeâ 
Terminator chemistry (Applied Biosystems). We used a short PCR fragment to amplify the 65bp 
fragments of the HPV genes. Then the amplified products were analyzed by electrophoresis in a 
3% agarose gel containing ethidium bromide and photographed. HPV was typed by direct DNA 
sequencing (ABI prism 377 DNA sequencer). Results were interpreted as positive when one of the 




We used to chi-square test to assess the association between demographics, cervical pathology, 





We recruited a total of 56 women in this study. The age ranged from 23 to 56 years, with a mean 
age of 42.96 years. Table 1 showed the demographic data of participants. HPV was detected in 20 
out of 56 (35.7%). There were 6 high-risk oncogenic HPVs (18, 51, 52, 56, 58, 68) detected in 
participants and the most prevalent subtypes detected were 18, 52, and 58 (20% each). Four low-
risk HPVs detected were 6, 53, 70, and 84.  
The frequency distribution of cytology lesions within the HPV positive and negative groups were 
shown in Table 2. Among participants, 15% of the atypical squamous cell of undetermined 
significance (ASC-US), 50% of low-grade intraepithelial lesions (LSIL), and 35% of high-grade 
intraepithelial lesions (HSIL) were HPV positive. In contrast, 8.3% of HSIL, 36% of LSIL, and 
55% of ASC-US were negative. There was a significant association between the severity of 
cervical lesions and HPV positivity (P < 0.004). HSIL had the highest positive predictive value to 
have HPV infection as 70% compared to 43.4% of LSIL and 9.3% of ASC-US.   
There was no significant difference in HPV prevalence among age and ethnic groups [Table 2]. 
Subtype 18 was more commonly seen in high-grade squamous intraepithelial lesions (HSIL). The 
distribution of HPV subtypes was presented in table 3. Among all participants, 11 did not require 
any interventions. A large loop excision of the transformation zone (LLETZ) was performed in 
11, and cervical biopsy in 34. The intervention measures were done according to the Sarawak 
General Hospital guideline for abnormal cervical smears. The follow-ups planned as scheduled as 
six-monthly, yearly, and returned to the routine call.  
 
Discussion  
Sarawak is the largest of 13 states in Malaysia with six major ethnic groups; Iban, Chinese, Malay, 
Bidayuh, Melanau and Orang Ulu, and more than 40 sub-ethnic groups. Although it has a relatively 
low population density compared to West Malaysia, it ranked at the highest incidence rate for 
cervical cancer nationwide. This study was the first HPV study among multi-ethnic women with 
abnormal cervical smears in Sarawak.  
In our study, the overall HPV prevalence in women with abnormal cervical smears was 35.7% 
with high-risk HPV prevalence of 26.7%. There was no significant difference between age and 
ethnicity. A few studies had described the HPV prevalence in Malaysian women with abnormal 
cervical smears over the last decade. Sharifah and colleagues reported in 2009 that the prevalence 
of HPV in 38 abnormal cervical smears was 95%, and the most prevalent genotypes were HPV 16 
and 52. The smears used in their study were collected from cytological archives, and 
approximately one-third was cancer cases [15]. Another study conducted in the North Eastern 
coastal part of West Malaysia revealed a 3% HPV prevalence for the general population, but 61.5% 
in abnormal pap smears [16]. A study conducted in Singapore and Southern Malaysia reported that 
39.7% in women with abnormal cytology [17]. Chong and colleagues presented that the overall 
prevalence of 46.7% among 180 women in Selangor, but their study included only five abnormal 
smears, all of which were positive for HPV [18]. 
Globally many studies have reported the prevalence of HPV and its subtypes, which varies widely 
across the different geographical regions and populations [12, 13]. This variables rate is due to 
different methods used for HPV detection (hybrid/PCR) and typing (primers), types of the studied 
materials (smears/frozen materials), anatomical localization, and population [14]. In our study, we 
used PCR to achieve a molecular diagnosis of HPV infection. PCR is the most commonly used 
technique as it can detect small fragments of DNA [19]. Two different pairs of primers 
(MY09/MY11 and GP5+/GP6+) can identify a wide range of HPVs and are most frequently used 
in clinical studies [18, 20].  
Most of the studies from West Malaysia reported the different distribution of HPV subtypes. The 
most prevalent subtypes were 16,18, 52, 58 [15-18, 21, 22]. In this study, the most frequent types 
detected were 18, 52, and 58, while we did not identify 16 in our participants. The HPV genotyping 
kit we used in this study had a wide range of detection for different HPV genotypes. Besides 6 
high-risk oncogenic HPVs (18, 51, 52, 56, 58, 68), additional 4 low-risk HPVs (6, 53, 70 and 84) 
were detected in present work. Interestingly, none of the previous studies conducted in West 
Malaysia has reported the presence of HPV 70.  
Recently a paper published from the neighbour state, Sabah, reported that 9.6% of HPV 
prevalence, which included the majority of normal smears and a few abnormal smears, with the 
most prevalent type detected in abnormal smears was 58 [23]. They also observed the prevalence 
of HPV 70 (16.7%) in participants from Sabah. These findings suggest that HPV 58 is the subtype 
frequently associated with abnormal smears in East Malaysia, and HPV 70 is relatively prevalent 
among women in this region compare to West Malaysia. One meta-analysis reported that HPV 58 
attributed to cervical intraepithelial neoplasia and cervical cancer in East Asia nearly four times 
higher than other continents [24]. A prospective study conducted in Taiwan noted that the long-
term risk of invasive cervical cancers was higher for subtype 58 compared to other non-HPV 16 
subtypes [25].  
There was one HIV positive participant, and she was found to be HPV negative, which was 
probably due to the practice of barrier contraceptive method. There was no case of multiple 
infections detected. There were 4 participants as a first time screening. Their first pap smear was 
done and straightaway to be seen in the colposcopic clinic, which suggested that the uptake of 
cervical screening programs by the public was low. According to the Ministry of Health Malaysia 
Annual Report 2017, cervical screening coverage was only 26.3%, although it aimed for 40% of 
all sexually active women between 20 – 65 years [26].  
We noted that there was a significant association between the severity of cervical lesions and HPV 
positivity (P < 0.004). HSIL had the highest positive predictive value to be HPV positive as 70% 
compared to 43.4% of LSIL and 9.3% of ASC-US. This finding supports that the prevalence 
increases with increased severity of cervical lesions as reported by other studies [4, 27].   
The HPV infection is preventable by prophylactic vaccination, which was proved to be effective 
and safe. Currently, there are two types available in Malaysia. The bivalent vaccine protects high-
risk oncogenic HPV 16 and 18, which account for 70% of cervical cancers, and the quadrivalent 
vaccine that targets additional subtypes 6 and 11, which causes 90% of genital warts [28, 29]. In 
Malaysia, the vaccine was approved in 2007, and the national program on HPV immunization was 
launched in 2010 [30]. In late 2014, nonavalent (9-valent) vaccine was approved in US, which 
extends the coverage to additional 5 high-risk oncogenic HPVs 31, 33, 45, 52 and 58 [31]. 
However, more comprehensive data on cost-effectiveness, affordability, and feasibility are still 
needed for resource-limited settings.  
We studied the prevalence of HPV among women with abnormal cervical smear for the first time 
in Sarawak. The sample size was relatively small, which may limit the statistical significance. The 
study included only participants with abnormal smears, so that the result may not be generalizable 
to the whole Sarawakian community. However, it may act as a stepping stone for future studies as 
it described HPV subtypes associated with abnormal cervical smears. Further studies with larger 
sample size and extensive coverage of other areas of Sarawak will help better understanding of 
HPV prevalence and distribution in the state. The identification of HPV subtypes in the local 
community may assist in implementing the appropriate strategies for cervical cancer prevention. 
Understanding the distribution of HPV subtypes is crucial to determine the most suitable HPV 
vaccines against the infection and cost-effective approach for the prevention of cervical cancer.  
 
Conclusion  
Distribution of HPV subtypes from women with abnormal smears from Sarawak indicated a high 
prevalence of HPV 18, 52, and 58. We also identified HPV 70, which has never been reported in 
West Malaysia. These findings could contribute valuable information for HPV vaccination 




Table1. Socio-Demographic characteristics of participants (n= 56) 
Characteristics Number Percent 
Age (years) 
 
23 – 68 
Mean - 42.96 
 
Ethnicity  
   Malay 
   Chinese 
   Bidayuh 












    Single 











Duration of relationship 
   <10 years 








   No child 
   1 child 
   2-5 children 












   <Secondary 
   Secondary 










Sexually transmitted infection 
   Yes 









   No 
   COCP 
   Injection & BTL 












No. of pap smear done before 
   Never 
   1-2 times 











   No 
   Biopsy 
   LLETZ 
 








   Negative 








Table 2. Prevalence of HPV among study participants  
Status Prevalence Total (56) 
 
p-value 



































































     
 
Table 3. Distribution of HPV subtypes in 20 abnormal cervical smears 
Lesions HPV Subtypes Total 6 18 51 52 53 56 58 68 70 84 
ASC-US - 1 - - - - 2 - - - 3 
LSIL 1 - 1 2 1 1 2 1 1 - 10 
HSIL - 3 - 2 - - -  1 1 7 
Total  1 4 1 4 1 1 4 1 2 1 20 
ASC-US – Atypical squamous cell of undetermined significance  
HSIL – High- grade squamous intraepithelial lesion 
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